Meine Merkliste  

2.862 Aktuelle Fachpublikationen von Future Medicine


Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity

15.05.2015 | Sze Ling Chan; Shengnan Jin; Marie Loh; Liam R Brunham, Pharmacogenomics, 2015

A major goal of the field of pharmacogenomics is to identify the genomic causes of serious adverse drug reactions (ADRs). Increasingly, genome-wide association studies (GWAS) have been used to achieve this goal. In this article, we review recent progress in the identification of genetic variants ...


Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review

12.05.2015 | Samantha Jarjour; Mathieu Barrette; Valérie Normand; Jean Lucien Rouleau; Marie-Pierre Dubé; Simon de Denus, Pharmacogenomics, 2015

Pharmacogenomic markers in the HLA coding genes have been associated with drug hypersensitivity of multiple drugs, including allopurinol. In this systematic review, we summarize the pharmacogenomic evidence available regarding allopurinol-induced cutaneous adverse drug reactions (cADRs). We found ...


Prevalence of antimitochondrial antibodies in autism spectrum subjects

08.05.2015 | Muhammad Iqbal; Shahid Bashir; Laila Al-Ayadhi, Future Neurology, 2015

ABSTRACT  Objective: Autism is a neurodevelopmental disorder characterized by impairment in verbal and nonverbal communication, repetitive and stereotypic behavior. Dysregulated immune system has a role in the pathogenesis of Autism. This study was designed to measure the prevalence of ...


Opportunities in pharmacogenomics for the treatment of Alzheimer's disease

08.05.2015 | Ramón Cacabelos; Clara Torrellas; Iván Carrera, Future Neurology, 2015

ABSTRACT  In Alzheimer's disease (AD), approximately 10–20% of direct costs are associated with pharmacological treatment. Pharmacogenomics account for 30–90% variability in pharmacokinetics and pharmacodynamics. Genes potentially involved in the pharmacogenomics outcome include pathogenic, ...


Emerging themes from the literature on circulating biomarkers of traumatic brain injury

08.05.2015 | Karolina Paziana; Frederick K Korley, Future Neurology, 2015

ABSTRACT  Objective diagnosis of traumatic brain injury (TBI) and early prediction of TBI-associated outcome remains a significant clinical challenge with major public health implications. The use of circulating biomarkers to quantify TBI has promise for real-time clinical decision making and may ...


Is there a link between the sleep–wake cycle and Alzheimer's pathology?

08.05.2015 | Jee Hoon Roh; David M. Holtzman, Future Neurology, 2015

Future Neurology May 2015, Vol. 10, No. 3, Pages 183-186.


Oxidative stress: a hallmark of Rett syndrome

08.05.2015 | Claudio De Felice; Cinzia Signorini; Silvia Leoncini; Thierry Durand; Lucia Ciccoli; Joussef Hayek, Future Neurology, 2015

Future Neurology May 2015, Vol. 10, No. 3, Pages 179-182.


The OPTIMISE data project: toward improving multiple sclerosis treatment

08.05.2015 | Paul M Matthews, Future Neurology, 2015

BIOGRAPHY  Paul Matthews speaks to Ellen Clarke, Commissioning Editor: Paul Matthews, OBE, MD, DPhil, FRCP, FMedSci is Head of the new Division of Brain Sciences at Imperial College, London. He was the founding Director of two leading research imaging centers, the University of Oxford Centre for ...


Treatment-resistant depression: experience of the first repetitive transcranial magnetic stimulation clinic in the UK

08.05.2015 | Rafael Euba; Irina Panihhidina; Andy Zamar, Future Neurology, 2015

ABSTRACT  Aim: To report the clinical outcomes of 62 treatment-resistant depressed patients treated with repetitive transcranial magnetic stimulation (rTMS) in the first rTMS clinic in the UK during 2013. Materials & methods: Sixty-two treatment-resistant depressed patients (12 of them bipolar) ...


Prion protein aggregation assays in the diagnosis of human prion diseases

08.05.2015 | Alison JE Green, Future Neurology, 2015

ABSTRACT  Sporadic Creutzfeldt–Jakob disease (sCJD) is the most common form of human prion disease and is associated with a progressive cognitive decline and death usually occurs within 6 months. Neuropathologically these diseases are characterized by the deposition of an abnormal form (PrPSc) of ...


Seite 3 von 287
Suche per e-Mail abonnieren

Sie erhalten passend zu Ihrer Suche die neusten Suchergebnisse per E-Mail. Dieser Service ist für Sie kostenlos und kann jederzeit abbestellt werden.

Ihr Bowser ist nicht aktuell. Microsoft Internet Explorer 6.0 unterstützt einige Funktionen auf Chemie.DE nicht.